The Lancet Neurology in conversation with

In this episode, Laura Hart and Elena Becker-Barroso speak with Niklas Mattsson-Carlgren (Lund University) about the use of blood biomarkers in the diagnosis and stratification of Alzheimer's disease. They discuss two particular plasma biomarkers—p-tau217 and eMTBR-tau243—including what they measure and how a proposed practical two-step approach that uses p-tau217 as an initial screen in a neurology clinic, and then eMTBR-tau243 for those who test positive, could support diagnostic decisions. 
Click here to read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00029-3/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode, Senior Editor Morgane Boillot speaks with Professor Cristina Tassorelli (University of Pavia, Italy) about recent advances in migraine prevention. 
Together with colleagues, Tassorelli has authored a Review in the journal examining the major developments in migraine-specific pharmacological treatments over the past decade, with a particular focus on therapies targeting the CGRP pathway. 
In this conversation, they explore what these advances mean for people living with migraine and for clinicians, discuss promising emerging targets for prevention and the future of biomarkers, and consider whether it is time to redefine the goals of migraine prevention with greater ambition. 
Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00477-6/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Our Editor-in-Chief, Elena Becker-Barroso, speaks with Inga Zerr (DZNE, Göttingen, Germany) and Simon Mead (UCL London, UK) about the latest advances in prion diseases. 
In collaboration with other experts, Zerr and Mead have authored a Series in the journal that covers the genetic factors behind these diseases, and new diagnostic and prognostic biomarkers.
Click here to read the full articles:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00451-X/fulltext
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00406-5/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Host Morgane Boillot chats with Dr Julia Greenland about a clinical trial of azathioprine in early Parkinson's disease. 
Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00386-2/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

In this episode, host Antonia Eisenkoeck, speaks with Ian McKeith, Emeritus Professor of Old Age Psychiatry at Newcastle University, UK. They delve into the history of dementia with Lewy bodies research, highlighting key milestones and breakthroughs. Discover insights into the current state of the field and what the future holds for understanding and treating this condition.
Click here to read the full articles of this series:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00363-1/fulltext
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00323-0/fulltext
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00314-X/fulltext
Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 
You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv